GLP 1 receptor agonists and dual incretin therapies are delivering measurable, outcome driven results: 12% to 27% relative risk reduction in major adverse cardiovascular events across CVOTs 13% to 14% reduction in cardiovascular death in meta analyses 11% to 14% reduction in hospitalization for heart failure 24% relative risk reduction in kidney outcomes in the dedicated FLOW trial with semaglutide Up to 15.8% weight loss with semaglutide 2.4 mg 20.2% weight loss with tirzepatide 15 mg in head to head obesity trials 66% to 93% reduction in progression from prediabetes to type 2 diabetes This is no longer about glucose (or weight loss) alone
But in patients with pre-existing inflammatory bowel disease, the inflammatory cascade in the colon may be sensitized or amplified by GLP-1 activation, potentially triggering flares or worsening existing inflammation
How Glutathione Oral Liquid Targets Melasma Glutathione is known as the master antioxidant. It neutralizes free radicals, detoxifies the body, and regulates the enzymes that produce melanin
Hello, Im Khrystyna Nehoda, an APRN and your partner in wellness at Toxwell Med Spa & Wellness in Hallandale Beach
Losing weight, especially for obese people, is crucial, as excessive weight is linked to an increased risk of diabetes, sleep apnea, heart disease, and cancer
IGF-1 LR3 and Semaglutide Together Goal: Body recomposition with a focus on fat loss
